Clinical trials: Gastric Cancer, completed
Gastric Cancer
The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis
To investigate the impact of the number of mesogastria containing metastatic lymph nodes on the prognosis of gastric cancer.
- Trial name
- NCT06697821
- Testing
- D2＋CME
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jichao Qin
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Gastric Cancer
Validation of a Model for Predicting Anastomotic Leakage
This study will validate a machine learning model for predicting anastomotic leakage of esophagogastrostomy and esophagojejunostomy.
- Trial name
- NCT05646290
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Jichao Qin
Gastric Cancer
Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC
he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers.
- Trial name
- NCT06696963
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Fujian Medical University
Gallstones, Gastric Cancer
The Incidence of Gallstones After Gastric Cancer Surgery
Through previous clinical observations and literature, we found that the incidence of gallstones in patients after gastric cancer radical resection was significantly higher than that in the normal population (4%).
- Trial name
- NCT04250402
- Testing
- Resection
- Where
- 2 sites in China
- Volunteers
- 1,019 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Gallstone, Gastric Cancer
The Incidence of Gallstones After Gastrectomy
To provide preventive and therapeutic strategies for participants with gallstones after gastric cancer by comparing the risk of postoperative gallbladder stone formation with two different resection ranges using the Roux-en-Y…
- Trial name
- NCT05965466
- Testing
- Distal gastrectomy and radical resection, Total gastrectomy and radical resection
- Where
- 2 sites in China
- Volunteers
- 531 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Anastomotic Leak, Gastric Cancer
Anastomotic Leak Testing in Gastrectomy
Anastomotic leak after radical gastrectomy is a serious complication. Intraoperative leak testing was often used to assess the integrity of the anastomosis.
- Conditions
- Anastomotic Leak, Gastric Cancer, Surgery, Testing, Reality
- Trial name
- NCT04292496
- Testing
- Introperative leak testing
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Nanchong Central Hospital
Gastric Cancer, Neoadjuvant Chemotherapy
Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy
In this study, consecutive 600 patients with LAGC(cT2-4NanyM0) who underwent NACT between Jan. 2010 and Jun. 2022 were identified from two tertiary hospitals.
- Conditions
- Gastric Cancer, Neoadjuvant Chemotherapy, Computed Tomography, Random Forest Model
- Trial name
- NCT06689462
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Previously untreated patients with limited metastatic stage (see protocol for details on criteria) will receive 4 cycles of FLOT (5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel).
- Trial name
- FLOT5 (NCT02578368)
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 183 people
- Sponsor
- Krankenhaus Nordwest
Lymph Node-negative, Gastric Cancer
Comparison of Long-term Outcomes Between Upfront Surgery and Neoadjuvant Therapy Followed by Surgery in Patients with Node-Negative Gastric Cancer
Patients with lymph node-negative gastric cancer, the prognosis of patients who underwent neoadjuvant therapy was poor than that of those who had upfront surgery.
- Trial name
- NCT06673472
- Where
- China
- Volunteers
- 1,081 people
- Sponsor
- Chang-Ming Huang, Prof.
Esophageal Cancer, Gastric Cancer
Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer
The aim of the study is to clarify whether octreotide therapy can reduce undesired postoperative weight loss, increase health-related quality of life and improve the appetite after surgery for esophageal or gastric cancer.
- Trial name
- OTIS (NCT04871204)
- Testing
- Octreotide Injection
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Fredrik Klevebro
Gastric Cancer Stage IV, Second-line Treatment
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies.
- Conditions
- Gastric Cancer Stage IV, Second-line Treatment, Ramucirumab Paclitaxel
- Trial name
- NCT06666582
- Testing
- Paclitaxel and ramucirumab
- Where
- Greece
- Volunteers
- 185 people
- Sponsor
- Hellenic Cooperative Oncology Group
Advanced or Inoperable Gastric Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms.
- Trial name
- NCT03427814
- Testing
- Pamiparib
- Where
- 65 sites in United States, Australia and 14 more
- Volunteers
- 136 people
- Sponsor
- BeiGene
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Peritoneal Carcinomatosis, Colorectal Cancer
HIPEC for Peritoneal Carcinomatosis
This is a clinical study investigating the new treatment of surgery combined with intraperitoneal mitomycin-C for patients with gastrointestinal cancer that has spread to the peritoneal (abdominal cavity) surface.
- Conditions
- Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma
- Trial name
- NCT02040142
- Testing
- HIPEC, Mitomycin C
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Albert Einstein College of Medicine
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene
Brain Cancer, Head and Neck Cancer
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer.
- Conditions
- Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer
- Trial name
- Dragon (NCT05427214)
- Testing
- Halcyon 4.0 system
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Gastric Adenocarcinoma
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional…
- Trial name
- NCT06645912
- Testing
- oral nutritional supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
Advanced Cancer, Refractory Cancer
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
This study is an open label, multicenter study in patients who have advanced, relapsed refractory GI cancer or are not relapsed/refractory but are intolerant to other therapies who, in the judgment of investigators, are…
- Conditions
- Advanced Cancer, Refractory Cancer, Tumor Gastric
- Trial name
- NCT04861987
- Testing
- PCS6422 and capecitabine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Processa Pharmaceuticals